Last updated on May 2020

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab


Brief description of study

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab.

The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.

Clinical Study Identifier: NCT03674567

Find a site near you

Start Over

Queen Mary Hospital

High West, Hong Kong
8.48miles
  Connect »